Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug aims to keep aggressive lymphoma at bay after chemo

NCT ID NCT07493109

Summary

This study is testing whether a drug called chidamide can help prevent cancer from coming back in patients with a specific type of lymphoma (DLBCL) who also have hepatitis B. Participants have already had successful initial chemotherapy (R-CHOP). The trial will compare patients who take chidamide as a long-term maintenance treatment to those who are simply observed, to see if the drug improves how long patients stay cancer-free.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Bethune Hospital of Jilin University

    RECRUITING

    Changchun, Jilin, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.